GlassScriptPhysician profile
Julian T Sison
NPI 1831524339
$5,142.03
in general payments reported to CMS, 2019-2025
21 companies · $419 in 2025
The $419 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,052 · 2020: $282 · 2021: $1,174 · 2022: $881 · 2023: $651 · 2024: $683 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,752.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,640.37 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,065.27 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $493.88 | 2019-2025 | Entyvio, Eohilia |
| Cook Medical LLC | $269.05 | 2019 | |
| Redhill Biopharma INC. | $262.31 | 2020-2024 | Talicia, Aemcolo, Movantik |
| Ironwood Pharmaceuticals, INC | $226.29 | 2021-2024 | Linzess |
| Boston Scientific Corporation | $190.33 | 2021 | |
| Gilead Sciences, INC. | $166.58 | 2020-2023 | |
| Celgene Corporation | $160.08 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $120.41 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $95.22 | 2019-2024 | Simponi Aria, Tremfya, Stelara |
| Shionogi INC | $95.02 | 2019 | |
| Nestle Healthcare Nutrition INC. | $74.16 | 2021 | |
| Intercept Pharmaceuticals, INC. | $72.53 | 2022-2024 | |
| Braintree Laboratories, INC. | $71.21 | 2022-2024 | Sutab, Suflave |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Micro-Tech Endoscopy USA, INC. | $46.81 | 2023-2024 | Blueboost, Snare |
| Axonics, INC. | $23.03 | 2023 | Axonics |
| Merck Sharp & Dohme LLC | $18.67 | 2023 | Dificid |
| Pfizer INC. | $17.31 | 2025 | |
| Vivus LLC | $17.15 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julian Sison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.